SARS-CoV-2 Vaccination in Primary Humoral Immunodeficiency: Experience from a German Lung Clinic

INTRODUCTION: During the COVID-19 pandemic, the effectiveness of vaccines against SARS-CoV-2 in immunodeficient patients not only did affect the individual risk of these vulnerable patients but endangered the selection of new variants of concern due to prolonged virus shedding by these patients. METHODS: In a tertiary center for pulmonary diseases, we investigated the immune response of 11 patients with primary humoral immunodeficiency and 13 healthy controls on the humoral and cellular level after full vaccination with an mRNA or vector vaccine against SARS-CoV-2. RESULTS: In the majority of patients (73%), we found antibodies against the spike protein above the threshold of positivity. Likewise, patients showed a promising cellular response: the upregulated production of INF

• Rosendahl, S.
• Trudzinski, F. C.
• Polke, M.
• Herth, F. J. F.
• Kreuter, M.
• Giese, T.